Conspiracy theories and pseudoscientific claims refuting the facts around Zika virus vaccines could be putting vulnerable people at risk, according to a new study published in Vaccine. By analyzing social media in real time, researchers were able to identify conversations about Zika virus vaccines and pinpoint the conspiracy theories being discussed.

An early-stage HIV vaccine clinical trial in South Africa has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection.

A viral protein known as NS5 is a promising target for vaccines against Zika and related viruses, according to National Institutes of Health (NIH) scientists and colleagues at Mount Sinai's Icahn School of Medicine. Their study, published online May 19, 2016 in Cell Host & Microbe, suggests that altering or removing the NS5 protein from Zika virus would allow the human body's own immune defenses to attack the virus.

The humble horseradish may not be much to look at, but a recent University of Illinois study shows that it contains compounds that could help detoxify and eliminate cancer-causing free-radicals in the body. "We knew horseradish had health benefits, but in this study, we were able to link it to the activation of certain detoxifying enzymes for the first time," says U of I crop scientist Mosbah Kushad.

A new study by the University of Liverpool's Institute of Ageing and Chronic Disease has identified food stuffs that can help prevent chronic inflammation that contributes to many leading causes of death. Inflammation occurs naturally in the body but when it goes wrong or goes on too long, it can trigger disease processes.

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

The University of Luxembourg today announced the publication of a research article in the internationally renowned scientific journal Nature Communications. The article is based on research on the interaction between microorganisms in the gut and the human body through the development of the artificial 'HuMiX' model.